Key Takeaways:
(Bloomberg) -- Boehringer Ingelheim and Zealand Pharma A/S’s experimental obesity drug, survodutide, produced an average weight loss of 16.6% in a late-stage trial, setting it up as a formidable future competitor to the blockbuster therapies from Eli Lilly & Co. and Novo Nordisk A/S.
“We are highly encouraged by the SYNCHRONIZE-1 topline results announced today by Boehringer Ingelheim, supporting the promise of survodutide as a differentiated therapy for people living with overweight or obesity and associated metabolic dysfunction,” David Kendall, MD, Chief Medical Officer of Zealand Pharma, said in a statement.
In the Phase III SYNCHRONIZE-1 study, adults treated with weekly injections of survodutide lost up to 16.6% of their body weight after 76 weeks, a statistically significant decrease compared to the 3.2% loss in the placebo group (p<0.0001). The trial also met its other co-primary endpoint, with 85.1% of participants on the drug achieving a body weight reduction of at least 5%, versus 38.8% for placebo.
The results intensify the race in the rapidly growing market for obesity treatments, which is projected to reach tens of billions of dollars in annual sales. Survodutide’s performance puts it in direct competition with established GLP-1 drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, potentially disrupting the current duopoly. Full data from the trial will be presented at the American Diabetes Association’s 2026 Scientific Sessions in June.
Survodutide is a dual-agonist that mimics two gut hormones: glucagon and glucagon-like peptide-1 (GLP-1). While the GLP-1 component suppresses appetite, the glucagon action is thought to directly target the liver to improve metabolic function and reduce liver fat. This dual mechanism may offer benefits beyond weight loss alone, particularly for related conditions like metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease.
The trial also showed a statistically significant reduction in waist circumference, a key indicator of visceral fat which is closely linked to cardiometabolic risk and impaired liver function. Boehringer is also studying the drug in two Phase III trials, LIVERAGE and LIVERAGE-Cirrhosis, for patients with MASH.
The safety profile was consistent with other GLP-1-based therapies. The most common side effects were mild-to-moderate gastrointestinal events, which occurred more frequently during the initial dose-escalation phase. No new safety concerns were identified.
Boehringer Ingelheim licensed the drug from Zealand Pharma and is solely responsible for its global development and commercialization. Zealand is eligible for royalties on global sales and up to EUR 315 million in potential milestone payments. The positive data also brings attention to other companies developing dual-agonist drugs, such as Altimmune Inc.
The strong efficacy data from SYNCHRONIZE-1 reinforces the potential for survodutide to capture a significant share of the obesity market. The upcoming presentation at the ADA conference will be a key catalyst for investors, providing more detailed insights into the drug's full clinical profile.
This article is for informational purposes only and does not constitute investment advice.
